RTW vs. JADE, SURE, APQ, TPOU, PRIM, VOX, INV, MAFL, IVPB, and SEED
Should you be buying RTW Biotech Opportunities stock or one of its competitors? The main competitors of RTW Biotech Opportunities include Jade Road Investments (JADE), Sure Ventures (SURE), APQ Global (APQ), Third Point Investors (TPOU), Primorus Investments (PRIM), Vox Valor Capital (VOX), Investment (INV), Mineral & Financial Investments (MAFL), Invesco Select Balanced Risk Alloc (IVPB), and Seed Innovations (SEED). These companies are all part of the "asset management" industry.
RTW Biotech Opportunities (LON:RTW) and Jade Road Investments (LON:JADE) are both small-cap financial services companies, but which is the superior investment? We will compare the two businesses based on the strength of their community ranking, dividends, valuation, media sentiment, earnings, analyst recommendations, institutional ownership, profitability and risk.
In the previous week, RTW Biotech Opportunities had 2 more articles in the media than Jade Road Investments. MarketBeat recorded 2 mentions for RTW Biotech Opportunities and 0 mentions for Jade Road Investments. RTW Biotech Opportunities' average media sentiment score of 0.21 beat Jade Road Investments' score of 0.00 indicating that RTW Biotech Opportunities is being referred to more favorably in the media.
RTW Biotech Opportunities has a beta of 0.6, suggesting that its share price is 40% less volatile than the S&P 500. Comparatively, Jade Road Investments has a beta of 0.19, suggesting that its share price is 81% less volatile than the S&P 500.
RTW Biotech Opportunities received 1 more outperform votes than Jade Road Investments when rated by MarketBeat users.
RTW Biotech Opportunities has a net margin of 1,994.76% compared to Jade Road Investments' net margin of 0.00%. RTW Biotech Opportunities' return on equity of 21.42% beat Jade Road Investments' return on equity.
RTW Biotech Opportunities has higher revenue and earnings than Jade Road Investments. Jade Road Investments is trading at a lower price-to-earnings ratio than RTW Biotech Opportunities, indicating that it is currently the more affordable of the two stocks.
11.1% of RTW Biotech Opportunities shares are owned by institutional investors. Comparatively, 56.1% of Jade Road Investments shares are owned by institutional investors. 12.3% of RTW Biotech Opportunities shares are owned by insiders. Comparatively, 23.2% of Jade Road Investments shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a stock will outperform the market over the long term.
Summary
RTW Biotech Opportunities beats Jade Road Investments on 11 of the 13 factors compared between the two stocks.
Get RTW Biotech Opportunities News Delivered to You Automatically
Sign up to receive the latest news and ratings for RTW and its competitors with MarketBeat's FREE daily newsletter.
This chart shows the average media sentiment of LON and its competitors over the past 90 days as caculated by MarketBeat. The averaged score is equivalent to the following: Very Negative Sentiment <= -1.5, Negative Sentiment > -1.5 and <= -0.5, Neutral Sentiment > -0.5 and < 0.5, Positive Sentiment >= 0.5 and < 1.5, and Very Positive Sentiment >= 1.5.
RTW Biotech Opportunities Competitors List
Related Companies and Tools
